Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acotiamide - Astellas Pharma/Zeria

Next Previous
Drug Profile

Acotiamide - Astellas Pharma/Zeria

Alternative Names: Acofide; Acotiamide hydrochloride hydrate; YM 443; Z-338; ZG-802

Latest Information Update: 28 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zeria
  • Developer Astellas Pharma; Zeria
  • Class Benzamides; Gastrokinetics; Small molecules; Thiazoles
  • Mechanism of Action Acetylcholine stimulants; Acetylcholinesterase inhibitors; Muscarinic M1 receptor antagonists; Muscarinic M2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-ulcer dyspepsia
  • Phase II Helicobacter infections

Most Recent Events

  • 19 Jun 2024 Zeria Pharmaceuticals and Agastra Lab agree to co-develop and market Acotiamide in Europe, USA and Canada for Non-ulcer dyspepsia
  • 02 Jan 2023 Phase-II development for Non-ulcer dyspepsia (In children, In adolescents) is ongoing in Japan (PO) (NCT04526119)
  • 24 Dec 2020 Phase-III clinical trials in Non-ulcer dyspepsia (In children, In adolescents) in Japan (PO) (NCT04526119)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top